Gao, Yanfei

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 113

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Ou, S.-H. I., Fujiwara, Y., Shaw, A. T., Yamamoto, N., Nakagawa, K., Fan, F., Hao, Y., Gao, Y., Jänne, P. A., & Seto, T. (2021) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 40